Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Increases By 7.4%

HilleVax, Inc. (NASDAQ:HLVX) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,300,000 shares, a growth of 7.4% from the November 30th total of 1,210,000 shares. Approximately 5.9% of the shares of the company are short sold. Based on an average trading volume of 195,800 shares, the short-interest ratio is presently 6.6 days.

Institutional Trading of HilleVax

Hedge funds have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. raised its position in shares of HilleVax by 8.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock valued at $153,523,000 after buying an additional 835,590 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in HilleVax in the 2nd quarter valued at approximately $6,960,000. Braidwell LP acquired a new position in HilleVax in the 3rd quarter valued at approximately $1,873,000. GSA Capital Partners LLP bought a new stake in shares of HilleVax in the 3rd quarter worth approximately $126,000. Finally, Trium Capital LLP acquired a new stake in shares of HilleVax during the 3rd quarter worth approximately $798,000. 86.42% of the stock is owned by institutional investors.

HilleVax Stock Performance

HilleVax stock opened at $2.07 on Thursday. HilleVax has a 52 week low of $1.55 and a 52 week high of $20.22. The firm has a market capitalization of $103.11 million, a PE ratio of -0.67 and a beta of 0.81. The business’s 50-day simple moving average is $1.90 and its 200-day simple moving average is $3.09.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.10). Research analysts forecast that HilleVax will post -2.64 earnings per share for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.